Programme
Monday 24 January
Chairs: Chris Holcombe & Sarah Vinnicombe

Minimally invasive techniques for therapeutic treatment of cancers

Risk-adapted tailored breast radiotherapy: one size no longer fits all

Risk-adapted axillary surgery including TAD and its practical aspects

What's new in DCIS: A grand challenge
Panel discussion
Chairs: Judith Bliss & Mairead Mackenzie

Pre-surgical provocation tests for clinical trials and management

Are CDK 4/6 inhibitors ready for clinical use?

Optimising systemic therapy for women with BRCA mutations: Current knowledge and future directions

Neoadjuvant anti-HER2 therapy enabled risk adaptation: An era to optimise practice
Panel discussion
Chairs: Sarah Pinder & Gareth Evans

Molecular evolution of breast cancer

Personalised breast cancer screening

Past, present and future directions in breast cancer genetics

Strategies to prevent breast cancer
Panel discussion
Chairs: Caroline Wilson and Leena Chagla

Should we be offering next generation sequencing for routine clinical use?

Immunotherapy for metastatic breast cancer

Optimal management and treatment sequencing of ER+ HER2- metastatic breast cancer

Role of surgery in metastatic breast cancer
Panel discussion
Promotional industry-led symposium organised and funded by Gilead Sciences Ltd.
Tuesday 25 January
Chairs: Professor Stephen Johnston
Chairs: Ingunn Holen and Thomas Hughes

Co-targeting CDK4/6 and AKT with endocrine therapy overcomes CDK4/6 inhibitor and endocrine therapy resistance in preclinical breast cancer models

The challenge of modelling of brain metastases - combining in vivo, cell culture and organotypic approaches to investigate brain extravasation

The role of gamma delta T cells in breast cancer development/metastasis

Understanding breast cancer through use of single-cell systems biology
Chairs: Anne Armstrong and Lesley Turner

Unmet need and follow-up

Breast Cancer Now's Helpline and patient focused resources

Identifying theory and evidence-based psychosocial factors associated with adherence to adjuvant hormonal therapy: understanding individual differences to tailor interventions

Supporting women with adherence to endocrine therapy following breast cancer: the SWEET programme
Chairs: Baroness Delyth Morgan and Catherine Harper-Wynne

Future of cancer services in the UK

Future vision for breast surgery

Future vision for radiotherapy

Future vision for pathology

Future vision for radiology

Future vision for clinical trials

Future vision for systemic therapies
Panel discussion
Chairs: Mark Verrill

Welcome and Introduction

Summary of the RxPONDER publication

